Area of research
Neurology · Surgery
Research interest
Research focused on Cancer research and Gemcitabine, with related work in Hepatoblastoma, Bromodomain, Pancreatic ductal adenocarcinoma. Notable publications include 'The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype', 'The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models', and 'The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors'.
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine
Novel PP2A-Activating Compounds in Neuroblastoma
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
Lerociclib diminishes stemness in pediatric sarcoma cell lines.
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models
Developing effective combination therapy for pancreatic cancer: An overview
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma
Sphingolipid metabolism and drug resistance in ovarian cancer
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer
Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study
JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors
The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype
Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin
Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma